On Mar. 6, 2020, Mount Sinai Health System and Harbour BioMed (HBM) announced a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.

The collaboration will also utilize the H2L2 Harbour Mice^® platform to generate monoclonal antibodies against the coronavirus SARS CoV 2 – COVID-19 (commonly known as COVID-19).

These fully human monoclonal antibodies could be used therapeutically for people who have been exposed to the virus, or prophylactically for individuals with a high risk of exposure, such as healthcare workers. The antibodies have the potential to prevent spread of the virus by blocking infection of cells.

Mount Sinai Innovation Partners (MSIP) is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry.

Harbour BioMed is a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases. The company is building its proprietary pipeline through internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.